Neurosense Therapeutics Ltd Stock Current Asset
| NRSNW Stock | USD 0.25 0.13 34.21% |
NeuroSense Therapeutics Ltd fundamentals help investors to digest information that contributes to NeuroSense Therapeutics' financial success or failures. It also enables traders to predict the movement of NeuroSense Stock. The fundamental analysis module provides a way to measure NeuroSense Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeuroSense Therapeutics stock.
Total Current Assets is likely to climb to about 5.1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 154 K in 2024. NeuroSense | Current Asset |
NeuroSense Therapeutics Ltd Company Current Asset Analysis
NeuroSense Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
NeuroSense Current Asset Historical Pattern
Today, most investors in NeuroSense Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NeuroSense Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of NeuroSense Therapeutics current asset as a starting point in their analysis.
NeuroSense Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
NeuroSense Total Assets
Total Assets |
|
In accordance with the recently published financial statements, NeuroSense Therapeutics Ltd has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
NeuroSense Fundamentals
| Return On Equity | -4.95 | ||||
| Return On Asset | -1.51 | ||||
| Number Of Shares Shorted | 1.95 K | ||||
| EBITDA | (10.63 M) | ||||
| Net Income | (11.28 M) | ||||
| Cash And Equivalents | 994 K | ||||
| Cash Per Share | 0.13 X | ||||
| Total Debt | 142 K | ||||
| Current Ratio | 8.08 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (8.45 M) | ||||
| Earnings Per Share | (0.94) X | ||||
| Number Of Employees | 18 | ||||
| Beta | 1.57 | ||||
| Total Asset | 3.18 M | ||||
| Retained Earnings | (32.07 M) | ||||
| Working Capital | (543 K) | ||||
| Net Asset | 3.18 M |
About NeuroSense Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeuroSense Therapeutics Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuroSense Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuroSense Therapeutics Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.